A guide to state-of-the-art cancer immunotherapy in translational cancer research
A volume in the Translational Oncology series, Immunotherapy in Translational Cancer Research explores the recent developments in the role that immunotherapy plays in the treatment of a wide range of cancers. The editors present key concepts, illustrative examples, and suggest alternative strategies in order to achieve individualized targeted therapy. Comprehensive in scope, Immunotherapy in Translational Cancer Research reviews the relevant history, current state, and the future of burgeoning cancer-fighting therapies. The book also includes critical information on drug development, clinical trials, and governmental resources and regulatory issues.
Each chapter is created to feature: development of the immunotherapy; challenges that have been overcome in order to scale up and undertake clinical trials; and clinical experience and application of research. This authoritative volume is edited by a team of noted experts from MD Anderson Cancer Center, the world’s foremost cancer research and care center and:
- Offers a comprehensive presentation of state-of-the-art cancer immunotherapy research that accelerates the pace of clinical cancer care
- Filled with the concepts, examples, and approaches for developing individualized therapy
- Explores the breath of treatments that reflect the complexity of the immune system itself
- Includes contributions from a panel international experts in the field of immunotherapy
Designed for physicians, medical students, scientists, pharmaceutical executives, public health and public policy government leaders and community oncologists, this essential resource offers a guide to the bidirectional interaction between laboratory and clinic immunotherapy cancer research.
| Editors |
|
vi | |
| Contributors |
|
vii | |
| Introduction |
|
ix | |
| 1 Translation in Immunology: The Role of Translational Biomarkers to Guide Clinical Use of Immunotherapy for Cancer |
|
1 | (11) |
|
|
|
|
| 2 Monoclonal Antibody Therapy |
|
12 | (12) |
|
|
|
|
| 3 Somatic Mutations and Immunotherapy |
|
24 | (13) |
|
|
| 4 Checkpoint Blockade |
|
37 | (17) |
|
|
|
|
|
|
| 5 Myeloid Leukemia Vaccines |
|
54 | (18) |
|
|
|
|
| 6 Cancer Vaccines for Solid Tumors |
|
72 | (19) |
|
|
|
|
|
|
| 7 Immunotherapy with Non-Genetically Modified T Cells |
|
91 | (10) |
|
|
| 8 Immunotherapy with Genetically Modified T Cells |
|
101 | (14) |
|
|
|
|
| 9 Immunomodulation with Adjuvants and Cytokines |
|
115 | (17) |
|
|
|
|
| 10 Immune Cell Migration in Cancer and Immunotherapy |
|
132 | (11) |
|
|
|
|
| 11 Repurposing of Drugs for Immunotherapy |
|
143 | (18) |
|
Jyothishmathi Swaminathan |
|
|
|
| 12 Immunomodulation with Radiation |
|
161 | (16) |
|
|
|
|
|
|
|
|
|
|
| 13 Good Manufacturing Practices Facilities for Cellular Therapy |
|
177 | (9) |
|
|
|
|
| 14 T Cell Receptor Mimic Antibodies |
|
186 | (15) |
|
|
|
|
| 15 Stem Cell Transplantation for Treatment of Malignancy |
|
201 | (14) |
|
|
|
|
| 16 Natural Killer Cell-Based Immunotherapy |
|
215 | (13) |
|
|
|
|
|
|
| 17 Immunologic Monitoring in Immuno- Oncology |
|
228 | (24) |
|
|
|
|
| 18 Cell-Based Therapies for Canine Cancer |
|
252 | (16) |
|
|
|
|
| 19 Interaction between Targeted Therapy and Immunotherapy |
|
268 | (18) |
|
|
|
|
|
|
|
|
| Index |
|
286 | |
Laurence J. N. Cooper, Associate Professor, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, USA.
Elizabeth A. Mittendorf, Professor, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Judy Moyes, Department of Pediatric Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
Sabitha Prabhakaran, Clinical Research Scientist, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Lisainfo e-raamatute kohta